A
AIM Vaccine / 艾美疫苗
Beijing HK-listed full-chain human vaccine group (HKEX 06660)
About AIM Vaccine / 艾美疫苗
Beijing HK-listed full-chain human vaccine group (AIM Vaccine / 艾美疫苗; HKEX 06660) — recombinant HBV, Vero rabies, HAV, mumps, HFRS and MPSV4 plus mRNA / PCV pipeline across multiple licensed manufacturing subsidiaries — mid-size China vaccine leftover beyond Biokangtai FIX / Pack 41 CanSinoBIO FIX / Walvax mega soft-skip. The company covers R&D through manufacturing and commercialization for human vaccines serving provincial and municipal immunization programs across China.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2011
- Headquarters
- China
- Listing
- IPO 2022
- Sector
- Biotech & Life Sciences
- Outcome tier
- Thoroughbred$100M+ revenue
News
Open roles
AIM Vaccine / 艾美疫苗 in its local ecosystem
The AIM Vaccine / 艾美疫苗 office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Source: Dealroom Talent Intelligence.
Global footprint
across markets
Market sentiment
An AI-synthesised read of the highest-engagement posts about AIM Vaccine / 艾美疫苗 on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See AIM Vaccine / 艾美疫苗 on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

